How Long Does It Take to See Weight Loss on a GLP-1?

Two clocks are running, and only one is printed on the label

Clock one is the labeled dose schedule. It is published and standardized, so you can look up the intended step for week 9. It is not a guarantee of what will happen to you: prescribers may delay an escalation, hold a dose, reduce a dose, or stop treatment because of tolerability, and the labels build that discretion in.

Clock two is your body weight. Nothing in the sources behind this article publishes a week-by-week weight curve, a typical week at which the scale first moves, or a typical number of days before appetite changes. We are not going to invent those numbers. The Mounjaro label does list appetite as a side effect: the most common adverse reactions reported in at least 5% of patients treated with Mounjaro are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain (per the Mounjaro label as of August 2026). The label records that it happens. It does not say when.

A caution about reading one clock off the other: a change in appetite is not a prerequisite for weight change, and movement on the scale is not itself proof that the medicine is working or that it is not. So when you are lying awake at week 3 doing arithmetic, the honest framing is this: clock one has a schedule you can look up. For clock two, no source cited here provides a reliable early checkpoint for an individual.

What the dose schedule actually says

Wegovy injection is escalated on a 4-week-per-step schedule: 0.25 mg once weekly for weeks 1-4, 0.5 mg for weeks 5-8, 1 mg for weeks 9-12, 1.7 mg for weeks 13-16, then a maintenance dose from week 17 onward. For weight reduction in adults, the Wegovy injection maintenance dose is 1.7 mg or 2.4 mg once weekly, and may be increased to a maximum of 7.2 mg once weekly if further weight reduction is needed and the dose is tolerated.

Form matters here. Wegovy is marketed in two distinct dosage forms under a single brand name and a single FDA label: WEGOVY (semaglutide) injection, solution, and WEGOVY (semaglutide) tablet. The tablet runs on a different clock. Wegovy tablets are escalated on a 30-day-per-step schedule: 1.5 mg once daily on days 1-30, 4 mg once daily on days 31-60, 9 mg once daily on days 61-90, then 25 mg once daily as the maintenance dose from day 91 onward.

Tirzepatide is a different molecule on a different schedule — and, strictly speaking, not a GLP-1-only medicine. The Zepbound label describes tirzepatide as a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, which selectively binds to and activates both receptors. "GLP-1" is the phrase people search for and the one used loosely throughout this article, but where semaglutide and tirzepatide are discussed together, "GLP-1-based medicines" is the more accurate description.

The recommended starting dosage of Zepbound for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks; the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage. After 4 weeks at 2.5 mg, the Zepbound dosage is increased to 5 mg subcutaneously once weekly, and may thereafter be increased in 2.5 mg increments after at least 4 weeks on the current dose. For the weight-reduction indication, the recommended Zepbound maintenance dosages are 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly. Zepbound is administered exclusively as a subcutaneous injection.

Read down a column, not across. These are two different molecules with separate FDA labels and separate titration schedules, shown side by side only because both are counted in weeks. Doses on the same row are not equivalent, not interchangeable, and not a comparison — 5 mg of one is not 5 mg of the other. Nothing in this table implies the two products work at the same rate or that you can switch between them at a matching dose.

A note on indication, because it changes which product a provider can prescribe for weight: Zepbound (tirzepatide) is FDA-indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition. By contrast, the Mounjaro FDA-approved indication is limited to glycemic control in type 2 diabetes mellitus; chronic weight management is not an approved indication under the Mounjaro label. And all three OZEMPIC injection indications are restricted to adults with type 2 diabetes mellitus.

The clock before the clock: getting to your first dose

Before either clock starts, you have to have the medication in your hand. This is the part patients most often underestimate.

Measured states most patients receive their medication within 3-7 business days once onboarding and medical review are complete. That is a company service estimate, not a guarantee, and it does not apply until a provider has prescribed.

The slower path runs through your insurance plan. Measured states that many insurance plans require a prior authorization before they will cover brand-name GLP-1-based medicines such as Ozempic, Wegovy, Mounjaro, or Zepbound. Coverage is decided by your plan, not by any telehealth company, and preauthorization is not a promise that the health insurance plan will cover the cost of the service or drug.

Federal rules set outer edges on parts of that wait, for the plans they cover. For plans and issuers subject to the applicable federal requirements, a pre-service (prior authorization) benefit determination generally must be made within 15 calendar days. If the answer is no, an internal appeal generally must be completed within 30 days where the appeal concerns a service the enrollee has not yet received. If that fails, standard external reviews are decided as soon as possible and no later than 45 days after the request was received.

These are separate ceilings, not a sequence you should expect to run end to end. Which of them apply depends on your plan type, your state, the urgency of the request, and whether the medication runs through the pharmacy benefit or the medical benefit — and most requests never reach the appeal stages at all. The general point holds without the arithmetic: a covered start can run behind a cash-pay start. Neither route changes the titration schedule once you begin; it changes when week 1 happens.

Why the first month is mostly titration

The starting dose is a tolerance dose, and the labels say so plainly. Zepbound's 2.5 mg step is explicitly not approved as a maintenance dosage, per the Zepbound prescribing information. On the oral side, the recommended starting dosage of Wegovy tablets is 1.5 mg once daily for days 1 through 30, and the label states the escalation exists specifically to reduce the risk of gastrointestinal adverse reactions.

The same label is equally plain that the schedule bends to the patient: "If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation," and if the 25 mg maintenance dosage is not tolerated, it directs prescribers to consider switching to Wegovy injection 1.7 mg once weekly. The printed schedule is the plan, not a fixed track.

This is also the window where side effects lead some people to stop. In the Zepbound weight-reduction trials, nausea was reported by 25% of patients on 5 mg, 29% on 10 mg, and 28% on 15 mg, versus 8% on placebo (label figures as of August 2026). Discontinuation rates differ substantially by drug, dose, trial, and population, so no single figure represents GLP-1 users generally. In SELECT — a cardiovascular outcomes trial in adults with overweight or obesity and without diabetes, not a weight-management registration trial — adverse events leading to permanent discontinuation occurred in 16.6% of semaglutide recipients versus 8.2% of placebo recipients (as of August 2026). That number describes that trial's population and should not be read as a general rate.

Stopping can interrupt treatment and may lead to weight regain, so side effects should be discussed promptly with your prescriber rather than managed by stopping on your own. Dose adjustments, delays, and holds are all things a prescriber can do.

What "on track" means in the published data

The only responder figure among the sources cited here is measured late. In STEP 1, 86.4% of participants (1,047) receiving semaglutide 2.4 mg achieved at least 5% weight loss at week 68, versus 31.5% (182) receiving placebo (as of August 2026).

No week-12 or week-16 checkpoint appears in these sources, so this article does not publish one. That is a statement about what is cited here, not a claim that no earlier data exist anywhere — secondary analyses of these trials do report earlier time points. The narrower and more useful point is that no validated way to predict an individual's result from an early measurement appears in the sources behind this article.

What shifts the timeline

Which population you are in. In the STEP 2 trial of 1,210 adults with overweight or obesity and type 2 diabetes, estimated mean change in body weight from baseline to week 68 was -9.6% with semaglutide 2.4 mg versus -3.4% with placebo (as of August 2026) — a smaller average than STEP 1, in a different population.

Which form. In the OASIS 4 trial, mean change in body weight at week 64 was -13.6% with oral semaglutide 25 mg once daily versus -2.2% with placebo (as of August 2026). That is a separate trial, not a head-to-head comparison against the injection.

Where you start. In the Zepbound label's Study 3 (72 weeks, following an intensive lifestyle intervention), mean body weight change was -18.4% with Zepbound 10-15 mg versus +2.5% with placebo (as of August 2026).

Gaps in dosing. If a Zepbound dose is missed, patients should administer it as soon as possible within 4 days (96 hours) after the missed dose; if more than 4 days have passed, the missed dose is skipped and the regular weekly schedule resumed. Coverage lapses and refill delays may create a dosing gap, which is why the insurance clock can matter clinically and not just financially. What to do after a gap depends on the specific product, how many doses were missed, and your prescriber's direction — follow your own product's label and ask your prescriber rather than generalizing from the Zepbound rule above.

Stopping, and what the data shows

In the Zepbound label's Study 4, a 52-week randomized withdrawal trial, mean body weight change from Week 36 to Week 88 was a further -5.5% among patients continuing Zepbound, while patients switched to placebo regained +14.0% (as of August 2026). These are group averages in one trial, not a prediction for any individual. Treatment length is part of the answer to "how long" — see what happens when you stop taking a GLP-1.

Do not stop, pause, or restart on your own to test this. If side effects or cost are driving the question, raise them with your prescriber first.

Safety information from the FDA labels

Everything in this section comes from the FDA prescribing information for Wegovy (semaglutide) and Zepbound (tirzepatide). It is not a complete summary of either label, and it is not medical advice. Read the full prescribing information for the product you are actually taking, and take direction from your prescriber over anything written here.

When to contact your prescriber rather than wait

Timing questions are the wrong frame for these. Contact your prescriber promptly — do not wait for a scheduled check-in — if you experience:

• Persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting. Both labels instruct clinicians to observe for signs of acute pancreatitis after initiation, and to discontinue if pancreatitis is suspected.
• Persistent vomiting, or an inability to keep fluids down. Both labels carry postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, and state that the majority of reported events occurred in patients who had gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea.
• Symptoms of gallbladder disease. Treatment with both products is associated with an increased occurrence of cholelithiasis and cholecystitis; the Wegovy label notes that substantial or rapid weight loss can itself raise the risk of gallstones.
• Signs of an allergic reaction, including anaphylaxis and angioedema. Both labels direct patients to seek medical attention promptly and discontinue if a hypersensitivity reaction occurs.
• Palpitations or a racing heartbeat at rest. The Wegovy label instructs patients to report this, and to discontinue if a sustained resting heart rate increase occurs.

Tell any healthcare provider that you are taking one of these medicines before any planned surgery or procedure requiring general anesthesia or deep sedation. Both labels carry rare postmarketing reports of pulmonary aspiration in patients with residual gastric contents despite reported adherence to preoperative fasting.

Pregnancy

Weight-loss treatment is not appropriate during pregnancy. Both labels state that weight loss offers no benefit to a pregnant patient and may cause fetal harm. The Zepbound label advises pregnant patients that weight loss is not recommended during pregnancy and to discontinue Zepbound when a pregnancy is recognized; the Wegovy label directs prescribers to discontinue Wegovy in pregnant patients using it for weight reduction. If you are pregnant, planning a pregnancy, or think you may be pregnant, raise it with your prescriber.

Do not combine these medicines

Concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended, per the Wegovy label. The Zepbound label states the same for its molecule: coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. Do not stack two of these products, and tell your prescriber about everything you are already taking.

Stomach and gut conditions

Neither product is recommended in patients with severe gastroparesis. Both labels report severe gastrointestinal adverse reactions more frequently than placebo in the weight-reduction trials. Tell your prescriber about any existing severe gastrointestinal disease before starting.

If you have diabetes

Hypoglycemia. Both products lower blood glucose and can cause hypoglycemia. The risk is increased when they are used together with insulin or an insulin secretagogue such as a sulfonylurea. In one Zepbound trial, hypoglycemia was reported in 10.3% of patients also taking a sulfonylurea versus 2.1% of those not. Both labels direct clinicians to monitor blood glucose and to consider reducing the dose of insulin or the secretagogue when starting. The Wegovy label notes its use in type 1 diabetes, or in combination with insulin, has not been evaluated. Symptoms of low blood sugar listed on the Wegovy label include anxiety, hunger, headache, irritability or mood changes, and confusion or drowsiness.

Diabetic retinopathy. Both labels also carry a warning about diabetic retinopathy complications in patients with type 2 diabetes, and it interacts directly with the timing question this article is about: rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. In a 2-year trial of semaglutide 0.5 mg and 1 mg once-weekly injection in adults with type 2 diabetes and high cardiovascular risk, diabetic retinopathy complications occurred in 3% of semaglutide-treated patients versus 1.8% on placebo, and the absolute risk increase was larger among patients who already had diabetic retinopathy at baseline (8.2% versus 5.2%) than among those who did not (0.7% versus 0.4%). Tirzepatide has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Both labels instruct that patients with a history of diabetic retinopathy should be monitored for progression — so tell your prescriber if you have one, and keep your eye care appointments while starting or escalating.

Absolute contraindications

Wegovy and Zepbound are both contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC), and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Wegovy is also contraindicated in patients with a prior serious hypersensitivity reaction to semaglutide or to any of its excipients.

Who these medicines are labeled for

Before any question about timing comes the question of whether these medicines are indicated for you at all. Wegovy and Zepbound are both indicated for weight reduction in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition.

The indications are written in those words rather than numbers. The numbers come from the registration trials behind them: Zepbound's Studies 1, 3 and 4 each enrolled adults with obesity defined as BMI 30 kg/m² or greater, or overweight defined as BMI 27 to under 30 together with a weight-related comorbid condition such as dyslipidemia, hypertension, obstructive sleep apnea, or cardiovascular disease. Mean baseline BMI across those trials ran from roughly 36 to 38.6 kg/m². Whether you fall inside that population, and whether treatment is appropriate for you, is a clinical judgment for a licensed provider who has evaluated you — and the answer may be that no medication is appropriate.

---

Last updated August 7, 2026. This article summarizes FDA prescribing information and published trial results for informational purposes. It is not medical advice, not a complete summary of any product label, and not a prediction of your results. Prescribing decisions belong to a licensed provider who has evaluated you. Read the full prescribing information for the product you are taking, and talk to your prescriber about any symptom or dosing question.